The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Clinical Study of WT2725 in Patients With Advanced Malignancies
Official Title: Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Study ID: NCT01621542
Brief Summary: This clinical study is designed to evaluate the safety, immunogenicity and antitumor activity of WT2725. WT2725 will be administered to patients with advanced malignancies known to overexpress WT1
Detailed Description: Treatment with other WT1 vaccines in clinical trials has shown evidence of immunogenicity and clinical response in various malignancies. This study will assist with determining which dose level(s) to use in future clinical studies and will evaluate both clinical and immunological response.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
The University of Chicago Medical Center, Chicago, Illinois, United States
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Name: Vice President Clinical Development and Medical Affairs, MD
Affiliation: Sumitomo Pharma America, Inc.
Role: STUDY_DIRECTOR